Goldman Sachs
LXRX icon

Goldman Sachs’s Lexicon Pharmaceuticals LXRX Stock Holding History

Goldman Sachs’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-190,000
Closed -$2.33M – 6526
2017
Q3 		$2.33M Buy
+190,000
New +$2.81M ﹤0.01% 3843
2016
Q3 		– Sell
-100,000
Closed -$1.44M – 7110
2016
Q2 		$1.44M Sell
100,000
-150,000
-60% -$2.03M ﹤0.01% 3887
2016
Q1 		$2.99M Sell
250,000
-90,000
-26% -$944K ﹤0.01% 3141
2015
Q4 		$4.53M Buy
+340,000
New +$4.18M ﹤0.01% 2921

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs's LXRX Position: Q2 2026 in Review

Goldman Sachs reduced its Lexicon Pharmaceuticals (LXRX) stake by 55% in Q2 2026, selling an estimated $1.14M and leaving 485,546 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #5095.

Goldman Sachs first reported a position in LXRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.73M in Q3 2015. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Goldman Sachs held 485,546 shares of Lexicon Pharmaceuticals worth $1.17M as of Q2 2026.
  • Goldman Sachs sold 584,971 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $1.14M.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5095 holding.
  • Goldman Sachs first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Lexicon Pharmaceuticals position peaked at $5.73M in Q3 2015.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.